These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 12960140

  • 1. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
    Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, Colombo T, Cherrington JM, Scanziani E, Nicoletti MI, Giavazzi R.
    Clin Cancer Res; 2003 Aug 15; 9(9):3476-85. PubMed ID: 12960140
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF, Gorelik E.
    Cancer Res; 2002 Oct 15; 62(20):5727-35. PubMed ID: 12384531
    [Abstract] [Full Text] [Related]

  • 8. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.
    Clin Cancer Res; 2008 Apr 01; 14(7):2210-9. PubMed ID: 18381963
    [Abstract] [Full Text] [Related]

  • 9. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
    Ning S, Laird D, Cherrington JM, Knox SJ.
    Radiat Res; 2002 Jan 01; 157(1):45-51. PubMed ID: 11754641
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68).
    Machida S, Saga Y, Takei Y, Mizuno I, Takayama T, Kohno T, Konno R, Ohwada M, Suzuki M.
    Int J Cancer; 2005 Mar 20; 114(2):224-9. PubMed ID: 15551349
    [Abstract] [Full Text] [Related]

  • 11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 12. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
    Zhou Q, Olivo M, Lye KY, Moore S, Sharma A, Chowbay B.
    Cancer Chemother Pharmacol; 2005 Dec 15; 56(6):569-77. PubMed ID: 16001166
    [Abstract] [Full Text] [Related]

  • 13. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
    Giavazzi R, Garofalo A, Ferri C, Lucchini V, Bone EA, Chiari S, Brown PD, Nicoletti MI, Taraboletti G.
    Clin Cancer Res; 1998 Apr 15; 4(4):985-92. PubMed ID: 9563894
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
    Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):678-89. PubMed ID: 15701856
    [Abstract] [Full Text] [Related]

  • 15. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
    Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):6966-71. PubMed ID: 16203789
    [Abstract] [Full Text] [Related]

  • 16. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2003 Apr 01; 9(4):1566-72. PubMed ID: 12684433
    [Abstract] [Full Text] [Related]

  • 17. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.
    Shaheen RM, Tseng WW, Davis DW, Liu W, Reinmuth N, Vellagas R, Wieczorek AA, Ogura Y, McConkey DJ, Drazan KE, Bucana CD, McMahon G, Ellis LM.
    Cancer Res; 2001 Feb 15; 61(4):1464-8. PubMed ID: 11245452
    [Abstract] [Full Text] [Related]

  • 18. Combined antiangiogenic and immune therapy of prostate cancer.
    Huang X, Raskovalova T, Lokshin A, Krasinskas A, Devlin J, Watkins S, Wolf SF, Gorelik E.
    Angiogenesis; 2005 Feb 15; 8(1):13-23. PubMed ID: 16132614
    [Abstract] [Full Text] [Related]

  • 19. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.
    Emanuel S, Gruninger RH, Fuentes-Pesquera A, Connolly PJ, Seamon JA, Hazel S, Tominovich R, Hollister B, Napier C, D'Andrea MR, Reuman M, Bignan G, Tuman R, Johnson D, Moffatt D, Batchelor M, Foley A, O'Connell J, Allen R, Perry M, Jolliffe L, Middleton SA.
    Mol Pharmacol; 2004 Sep 15; 66(3):635-47. PubMed ID: 15322256
    [Abstract] [Full Text] [Related]

  • 20. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
    Sirotnak FM, She Y, Lee F, Chen J, Scher HI.
    Clin Cancer Res; 2002 Dec 15; 8(12):3870-6. PubMed ID: 12473602
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.